NCT06159101View on ClinicalTrials.gov

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

May 28, 2024

Study Completion Date

May 28, 2024

Conditions
Healthy Male Volunteers
Interventions
DRUG

HLX13

A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.

DRUG

CN-sourced ipilimumab

A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.

DRUG

EU-sourced ipilimumab group

A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.

DRUG

US-sourced ipilimumab group

A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.

Trial Locations (1)

Unknown

RECRUITING

The Second Hospital of Anhui Medical University, Anhui

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY